DeepMed Research

Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Clinical Trials

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Phase 2

Active, not recruiting

Conditions: Other Cancer
Breast Cancer
Gastrointestinal Cancer
Non Small Cell Lung Cancer

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-03

Lead Sponsor: Fondazione per la Medicina Personalizzata

Target Recruit Count: 400

Registration Number: NCT04591431

Locations: 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹
Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹
I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

Conditions: NSCLC

Interventions: Drug: Bevacizumab
Drug: Erlotinib
Drug: Afatinib
Drug: Osimertinib
Drug: Gefitinib
Drug: Dacomitinib
Drug: Icotinib

First Posted Date: 2020-10-05

Last Posted Date: 2020-10-20

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 272

Registration Number: NCT04575415

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Phase 2

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer Stage IIIA

Interventions: Drug: Erlotinib
Drug: Almonertinib
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2020-07-02

Last Posted Date: 2020-07-02

Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 168

Registration Number: NCT04455594

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Advanced Solid Tumors
Colorectal Cancer

Interventions: Drug: GDC-6036
Drug: Erlotinib
Drug: Cetuximab
Drug: Atezolizumab
Drug: Bevacizumab
Drug: GDC-1971
Drug: Inavolisib

First Posted Date: 2020-06-29

Last Posted Date: 2025-05-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 498

Registration Number: NCT04449874

Locations: 🇮🇱
Sheba Medical Center - PPDS, Ramat Gan, Israel
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States

and more 71 locations

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Phase 2

Recruiting

Conditions: Cancer
Tumors
Neoplasms
Neoplasia

Interventions: Drug: Vemurafenib plus Cobimetinib (combination)
Drug: Trastuzumab plus Pertuzumab (combination)
Drug: Alectinib
Drug: Axitinib
Drug: Erlotinib
Drug: Atezolizumab
Drug: Avelumab
Drug: Trastuzumab emtansine
Drug: Vismodegib
Drug: Niraparib

First Posted Date: 2020-04-10

Last Posted Date: 2022-10-26

Lead Sponsor: Ulrik Lassen

Target Recruit Count: 300

Registration Number: NCT04341181

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark

and more 4 locations

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib (Gi(l)otrif®)
Drug: Erlotinib (Tarceva®)
Drug: Osimertinib (Tagrisso®)
Drug: Gefitinib (IRESSA®)

First Posted Date: 2019-11-27

Last Posted Date: 2023-05-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 462

Registration Number: NCT04179890

Locations: 🇬🇧
Royal Marsden Hospital, London, United Kingdom

Erlotinib for Hepatocellular Carcinoma Chemoprevention

Phase 2

Not yet recruiting

Conditions: Cirrhosis, Liver

Interventions: Drug: Erlotinib Hydrochloride

First Posted Date: 2019-11-21

Last Posted Date: 2024-08-12

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 30

Registration Number: NCT04172779

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Phase 1

Terminated

Conditions: Advanced Solid Tumor
Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions: Drug: LY3499446
Drug: Docetaxel
Drug: Abemaciclib
Drug: Cetuximab
Drug: Erlotinib

First Posted Date: 2019-11-15

Last Posted Date: 2021-11-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 5

Registration Number: NCT04165031

Locations: 🇦🇺
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Indiana Univ Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 1 locations

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Phase 4

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib HCl 150 mg
Drug: Tarceva®

First Posted Date: 2019-10-30

Last Posted Date: 2019-10-30

Lead Sponsor: Quadras Scientific Solutions

Target Recruit Count: 24

Registration Number: NCT04145570

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy